{"id":"W3199693232","doi":"10.1177/17588359211034708","title":"New approaches to first-line treatment of advanced renal cell carcinoma","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Exelixis","keywords":"Axitinib; Medicine; Nivolumab; Pazopanib; Pembrolizumab; Cabozantinib; Sunitinib; Ipilimumab; Renal cell carcinoma; Oncology; Tyrosine-kinase inhibitor; Internal medicine; Avelumab; Kidney cancer; Lenvatinib; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005002402,0.0007096069,0.001083295,0.002062432,0.0002261222,0.0007619043,0.0006743958,0.0006299629,0.003784842],"category_scores_gemma":[0.0004739227,0.0002110949,0.0006348556,0.001438191,0.0003135758,0.001010491,0.0005073649,0.002083112,0.001825472],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005692556,"about_ca_system_score_gemma":0.0008394324,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000827831,"about_ca_topic_score_gemma":0.00227743,"domain_scores_codex":[0.999811,0.00003594746,0.00002718925,0.00003303733,0.00007761941,0.00001529785],"domain_scores_gemma":[0.9998248,0.00008105618,0.00002835512,0.000005620542,0.00004610829,0.00001406258],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000752878,0.00008527777,0.0001051051,0.02107804,0.0001167101,0.0001307733,0.00004368354,0.0003210765,0.001541539,0.003782235,0.02731099,0.9454093],"study_design_scores_gemma":[0.00003418083,0.0001254353,0.0005877698,0.0040369,0.0001343065,0.0008775824,0.00003009919,0.00009681064,0.0003505071,0.001538959,0.992173,0.00001462389],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008084555,0.9985304,0.000114069,0.0001957815,0.0001702311,0.000005759306,0.00001725948,0.000007385334,0.0008782265],"genre_scores_gemma":[0.0004052737,0.9987283,0.0001651213,0.0001837032,0.0001228815,0.000006101398,0.00003031976,0.000001245038,0.0003571353],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003784842,"threshold_uncertainty_score":0.01266152,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1690109399906946,"score_gpt":0.3992702987299874,"score_spread":0.2302593587392927,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}